Anavex Life Scie - AVXL STOCK NEWS

Anavex Life Sciences (Nasdaq: AVXL) has appointed Professor Dr. Audrey Gabelle, MD, PhD to its Scientific Advisory Board. Dr. Gabelle, a specialist in predictive, personalized medicine and digital health in Alzheimer's disease, brings extensive expertise as a Professor of Neurology at Montpellier University.

Dr. Gabelle's credentials include managing 400+ memory centers within the French network, authoring 200+ peer-reviewed scientific papers, and 10+ years of experience in clinical Phase I-IV trials. She has expertise in diagnosis and biomarkers through the NeuroCognition biobank, which contains over 35,000 samples. Her recent focus includes real-world evidence, digital health strategies, and AI, with training from Columbia and Harvard Universities.

The appointment aims to support the development of blarcamesine (ANAVEX®2-73), an oral treatment for Alzheimer's disease that has shown clinically meaningful improvement and good safety profile.

Anavex Life Sciences (Nasdaq: AVXL) announced that Dr. Marwan Noel Sabbagh, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board, delivered an oral presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders in Abu Dhabi, UAE (April 18-20, 2025).

The presentation, titled 'Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial,' was part of a conference that brought together healthcare professionals, researchers, and advocates from the MENA region, USA, and Europe to discuss Alzheimer's disease and related disorders, with a focus on region-specific healthcare delivery.

Anavex Life Sciences (NASDAQ: AVXL) announced positive results from its Phase IIb/III ATTENTION-AD open-label extension trial of oral blarcamesine for Early Alzheimer's Disease, with data through 192 weeks presented at AD/PD 2025 Conference.

The study demonstrated that early and continuous treatment with blarcamesine showed significant benefits in reducing clinical decline. Key findings include:

• Significant improvement in cognitive function (ADAS-Cog13) with early treatment (LS mean difference -3.83, P = 0.0165)
• Improved functional outcomes (ADCS-ADL) in early treatment group (LS mean difference +4.30, P = 0.0206)
• Favorable safety profile with no treatment-related deaths or severe adverse events
• Reduced dizziness side effects (from 25.2% to 9.6%) with adjusted titration schedule

Currently, 74 participants are receiving blarcamesine through the Compassionate Use Program, with some patients on treatment for over 9 years.

Anavex Life Sciences (Nasdaq: AVXL) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference, scheduled for April 7-10, 2025. The company's President & CEO, Christopher U Missling, PhD, will deliver a presentation on Monday, April 7th, 2025, at 3:45 PM ET.

Anavex, a clinical-stage biopharmaceutical company, specializes in developing innovative treatments for various conditions including:

• Alzheimer's disease
• Parkinson's disease
• Schizophrenia
• Neurodevelopmental disorders
• Neurodegenerative diseases
• Rett syndrome
• Other CNS disorders

Interested parties can access the live audio webcast through the Investors section of www.anavex.com. An archived version of the presentation will be made available later the same day.

Anavex Life Sciences (Nasdaq: AVXL) has announced its participation in the 45th Annual TD Cowen Health Care Conference, taking place March 3-5, 2025, at the Boston Marriott Copley Place. Christopher U Missling, President & Chief Executive Officer, will present on Monday, March 3rd, 2025, at 9:50 AM ET.

The clinical-stage biopharmaceutical company, which focuses on developing innovative treatments for neurological conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome, will provide a live audio webcast of the presentation through their website's Investors section. An archived version will be made available later the same day.

Anavex Life Sciences (NASDAQ: AVXL) reported its fiscal 2025 Q1 financial results, highlighting significant developments in its Alzheimer's disease treatment program. The company's oral treatment blarcamesine demonstrated a 36.3% slowdown in clinical progression at 48 weeks, and 49.8% in patients with SIGMAR1 wild-type gene.

Financial results show cash and equivalents of $120.8 million as of December 31, 2024, providing an estimated 4-year runway. Q1 net loss increased to $12.1 million ($0.14 per share) compared to $8.6 million ($0.11 per share) in the previous year. R&D expenses rose to $10.4 million from $8.7 million, while G&A expenses increased to $3.1 million from $2.7 million.

The company secured a new composition of matter U.S. Patent for ANAVEX®2-73, valid until July 2039, covering crystalline forms and various delivery methods.

Anavex Life Sciences (Nasdaq: AVXL) has scheduled its fiscal 2025 first quarter financial results announcement for Wednesday, February 12, 2025. The company will host a conference call and webcast at 8:30 am ET on the same day, where management will review financial results and provide updates on the company's growth strategy.

The event will include a question-and-answer session following management's presentation. Investors can access the live webcast through the company's website at www.anavex.com, or join the conference call by dialing 1 929 205 6099 (U.S. participants) using Meeting ID# 828 2995 9982 and passcode 308966. A replay will be available on the company's website for up to 30 days.

Anavex Life Sciences (Nasdaq: AVXL) has been granted a new U.S. Patent (No. 12,180,174) for crystalline forms of ANAVEX®2-73 (blarcamesine) dihydrogen phosphate salt. The patent covers crystalline forms, freebase, transdermal patches, and enteric coated oral dosage forms for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer's and Parkinson's disease.

The patent will remain in force until at least July 2039 and expands the company's existing intellectual property portfolio, which includes several U.S. Patents (Nos. 10,413,519; 10,966,952; 11,661,405; and 11,498,908). The dihydrogen phosphate crystals enable convenient once-daily oral dosing and transdermal patch delivery options, potentially improving patient compliance.

Anavex Life Sciences announced the peer-reviewed publication of Phase IIb/III trial results for oral blarcamesine (ANAVEX®2-73) in The Journal of Prevention of Alzheimer's Disease. The study demonstrated that once-daily oral blarcamesine significantly slowed clinical progression by 36.3% at 48 weeks in early Alzheimer's Disease patients, and by 49.8% in the SIGMAR1 wild-type gene group on the ADAS-Cog13 cognitive endpoint.

The drug showed a favorable safety profile with no associated neuroimaging adverse events. Blarcamesine works through SIGMAR1 activation, inducing autophagy and restoring cellular homeostasis. The treatment could represent a novel approach for early Alzheimer's disease, potentially serving as a complementary or alternative option to injectable anti-beta amyloid drugs. The data is currently under review by the EMA as part of an MAA filing.